News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Microbix Biosystems Inc. Signs Letters of Intent to License its Flu Vaccine Yield Enhancement Technology
December 14, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TORONTO, Dec. 14 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) has signed two Letters Of Intent with companies outside North America which are interested in licensing the VIRUSMAX(TM) technology on a non-exclusive basis.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
January 5, 2026
·
3 min read
·
Annalee Armstrong
Obesity
Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month
January 5, 2026
·
2 min read
·
Dan Samorodnitsky
Layoff Tracker
Nido Will Close Following Lead Candidate’s Disappointing Phase II Results
January 2, 2026
·
98 min read
·
BioSpace Editorial Staff
Drug pricing
Pfizer Leads Industry-Wide Surge in Drug Prices for 2026 Despite Political Pressure
January 2, 2026
·
2 min read
·
Nick Paul Taylor
